Risk Factors Update Summary

• Net cash used in investing activities decreased significantly from $144.0 million in 2022 to $5.0 million in 2023.
• The company may need to secure additional funding to avoid delays or reduce research programs. This could dilute stock ownership and impact stock price.
• Third-party payors may require additional studies or regulate prices, impacting research and development.UT:
• Stock-based compensation modification decreased from $317,000 to $163,000, impacting remaining service period by approximately $98,000.
• The company authorized the issuance of 65,000,000 shares of common stock and 2,500,000 shares of preferred stock, a change from the previous authorization.
• The company's ability to protect intellectual property is crucial for commercialization success and may impact its ability to compete effectively.
• Pricing pressures globally and in the U.S. may impact revenue. Expect continued focus on regulating pricing.
• The company's ability to commercialize products heavily depends on obtaining and maintaining necessary regulatory approvals.
• Sales of common stock in private placements and equity financing arrangements may impact market price.
• The company's future success heavily relies on the successful development and commercialization of gedatolisib.
• The Policy outlines recoupment of Erroneously Awarded Compensation, including pre-tax recoupment of excess amounts.
• Net cash provided by financing activities increased from $120.3 million in 2022 to $64.9 million in 2023.
• Restricted stock outstanding decreased from 3,273 to 1,958 shares at December 31, 2023.
• The company issued pre-funded warrants to purchase 5,747,787 shares of common stock at an exercise price of $0.001 per share.
• The company's success is highly uncertain and dependent on the successful completion of clinical trials and regulatory approvals.
• The company faces significant competition in the biopharmaceutical industry, impacting its ability to compete effectively.
• Calculation of Erroneously Awarded Compensation includes excess shares received and accrued earnings on notional amounts.
• Increased compliance costs and legal risks due to evolving data privacy regulations and uncertainties.
• Legislative changes may require manufacturers to engage in price transparency or limit drug price increases.
• Financing activities in 2023 included net proceeds from a pre-funded warrants offering and ATM offering totaling $64.4 million.
• Recoupment methods include canceling future incentives or requiring repayment by Executive Officers promptly.
• Increased legal, accounting, and compliance expenses as a public company compared to a private company.
• The success of CELsignia tests depends on attracting pharmaceutical partnerships and demonstrating advantages on a cost-competitive basis.
• Privacy and security laws are rapidly evolving, impacting the collection and processing of personal data.
• The company amended its Certificate of Incorporation to increase the authorized number of shares of common stock to 6,956,450 with an adjusted exercise price of $8.05 per share.
• The Company believes utilization of third-party reports accurately reflects expenses incurred.
• Unrecognized compensation cost related to stock options and restricted stock increased from $3,347,075 to $4,255,020 at December 31, 2024.
• Changes in estimates may become more significant as the VIKTORIA-1 Phase 3 and CELC-G-201 Phase 1b/2 trials progress.
• The Company's auditor changed from Boulay PLLP to Boulay LLP in March 2024.
• Total stockholders' equity increased from $133.8 million in 2022 to $139.8 million in 2023.